Stockscreener 앱 받기
5.08
3.61%
-0.19
시간 외 거래:
5.05
-0.03
-0.59%
전일 마감가:
$5.27
열려 있는:
$5.17
하루 거래량:
179.91K
Relative Volume:
0.63
시가총액:
$70.09M
수익:
-
순이익/손실:
$-56.20M
주가수익비율:
-1.423
EPS:
-3.57
순현금흐름:
$-39.97M
1주 성능:
+13.90%
1개월 성능:
-24.29%
6개월 성능:
-11.81%
1년 성능:
-72.83%
1일 변동 폭
$5.04
$5.305
1주일 범위
$4.3829
$5.34
52주 변동 폭
$4.21
$20.00
Annovis Bio Inc Stock (ANVS) Company Profile
명칭
Annovis Bio Inc
전화
484-875-3192
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
ANVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
5.08 | 70.09M | 0 | -56.20M | -39.97M | -6.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-25 | 업그레이드 | Maxim Group | Hold → Buy |
| 2023-12-29 | 개시 | Canaccord Genuity | Buy |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
Annovis Bio (NYSE: ANVS) Committed To Ensuring Highest Standards In Buntanetap Trials - Barchart
Annovis Bio stock hits 52-week low at $4.52 amid market challenges - Investing.com Canada
When (ANVS) Moves Investors should Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Eyes Clear Path Forward For Buntanetap - Barchart
Annovis Bio, Inc. (NYSE:ANVS) Short Interest Update - MarketBeat
Royal Bank of Canada (RY-N) QuotePress Release - The Globe and Mail
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Annovis Bio (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Investor Webcast - Barchart
Annovis Bio, Inc. Appoints William Fricker to Serve as Chief Financial Officer on an Interim Basis - Marketscreener.com
Annovis Bio Announces Investor Webcast to Share Key Updates - MSN
Annovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials - TipRanks
Form 424B5 Annovis Bio, Inc. - StreetInsider.com
Annovis Bio appoints interim CFO By Investing.com - Investing.com Nigeria
7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline - BioSpace
Annovis Bio appoints interim CFO - Investing.com
Annovis Bio Appoints William Fricker as Interim CFO - TipRanks
(ANVS) On The My Stocks Page - Stock Traders Daily
Annovis Bio (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace - Barchart
We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate - Simply Wall St
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace - GlobeNewswire
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s - The Bakersfield Californian
Annovis Bio (NYSE: ANVS) to Present Recent Achievements, Strategic Outlook During Investor Webcast - Barchart
Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace - PR Newswire
/C O R R E C T I O N -- Today's Marketplace/ - Quantisnow
Down Syndrome Market expected to rise | Companies- Eisai, AC Immune, Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, Annovis Bio, AelisFarma, Kinopharma, NeuroNascent, Pharmasum Thera - Barchart
Annovis Bio (NYSE: ANVS) Schedules Investor Webcast to Share Clinical and Strategic Updates - Barchart
Annovis to Host Year-End Investor Webcast on December 11, 2024 - The Manila Times
Annovis Bio to Host Key Investor Update on Alzheimer's, Parkinson's Phase 3 Studies - StockTitan
Brokerages Set Annovis Bio, Inc. (NYSE:ANVS) Target Price at $32.17 - MarketBeat
Annovis Bio (NYSE: ANVS) Paving The Way For NDA Submission - Barchart
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MSN
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MSN
When the Price of (ANVS) Talks, People Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Concludes Q3 with Milestones, FDA-Cleared Phase 3 Program for Alzheimer’s - Barchart
Q4 Earnings Forecast for Annovis Bio Issued By HC Wainwright - MarketBeat
Annovis Bio (NYSE: ANVS) CEO To Showcase Buntanetap’s Dual Benefits At NIA Workshop - Barchart
Veravas and Phanes Biotech Collaborate to Innovate Alzheimer’s Disease Testing - MyChesCo
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - GlobeNewswire
Annovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial Backing - Barchart
Annovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Annovis sees cash runway for Phase 3 preparatory studies, entering AD study - Nasdaq
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely? - Yahoo Finance
Annovis Bio Inc (ANVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.76%
1.06%
자본화:
|
볼륨(24시간):